z-logo
open-access-imgOpen Access
Multidrug‐Resistant and Extensively Drug‐Resistant Tuberculosis: The National Institute of Allergy and Infectious Diseases Research Agenda and Recommendations for Priority Research
Author(s) -
Anthony S. Fauci
Publication year - 2008
Publication title -
the journal of infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.69
H-Index - 252
eISSN - 1537-6613
pISSN - 0022-1899
DOI - 10.1086/587904
Subject(s) - tuberculosis , medicine , mycobacterium tuberculosis , population , infectious disease (medical specialty) , immunology , human immunodeficiency virus (hiv) , disease , drug resistance , mortality rate , extensively drug resistant tuberculosis , environmental health , virology , biology , pathology , microbiology and biotechnology
Globally tuberculosis (TB) is one of the leading causes of death due to an infectious disease second only to HIV/AIDS. Estimates suggest that approximately one-third of the worlds population is infected with Mycobacterium tuberculosis the microbe that causes TB and approximately 10% of infected individuals will develop active TB at some point in their lives. For individuals also infected with HIV the likelihood of developing active TB after infection is much higher. In 2006 approximately 9.2 million people globally developed active TB and it is estimated that 1.7 million people died as a result of TB including 2 HIV-infected individuals. Although estimates suggest that the rates of new cases and deaths due to TB show signs of slowing throughout the world recent increases in rates of drug-resistant TB have the potential to reverse these gains. (excerpt)

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom